¼¼°èÀÇ Ã¼¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå
Extracorporeal CO2 Removal Devices
»óǰÄÚµå : 1655515
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 193 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Ã¼¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀåÀº 2030³â±îÁö 1¾ï 5,190¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 1¾ï 730¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Ã¼¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀåÀº 2030³â¿¡´Â 1¾ï 5,190¸¸ ´Þ·¯¿¡ ´ÞÇϸç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 6.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀΠü¿Ü½Ä CO2 ±â°è´Â CAGR 6.6%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 8,990¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÏȸ¿ë ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 5.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2,940¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 5.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Ã¼¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀåÀº 2024³â¿¡ 2,940¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 2,360¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 5.5%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 5.1%¿Í 5.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Ã¼¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ü¿Ü CO2 Á¦°Å±â°¡ È£Èí±â °ü¸®¿¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â?

ü¿Ü ÀÌ»êȭź¼Ò Á¦°Å(ECCO2R) Àåºñ´Â ±âÁ¸ÀÇ ÀΰøÈ£Èí¿¡ ´ëÇÑ ÃÖ¼Ò Ä§½ÀÀû ´ë¾ÈÀ» Á¦°øÇÔÀ¸·Î½á ÁßÁõ È£Èí±â Áúȯ °ü¸®¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖÀ¸¸ç, ȯÀÚÀÇ Ç÷¾×¿¡¼­ ÀÌ»êȭź¼Ò(CO2)¸¦ ü¿Ü·Î Á¦°ÅÇÏ¿© ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), ±Þ¼ºÈ£Èí°ï¶õÁõÈıº(ARDS) ¹× ±âŸ ÀÌ»êȭź¼Ò ÃàÀûÀÌ ¿ì·ÁµÇ´Â ÆóÁúȯ ȯÀڵ鿡°Ô µµ¿òÀ» ÁÝ´Ï´Ù. (COPD), ±Þ¼º È£Èí°ï¶õ ÁõÈıº(ARDS) ¹× CO2 ÃàÀûÀÌ ½É°¢ÇÑ ¹®Á¦°¡ µÇ´Â ±âŸ Æó Áúȯ ȯÀڵ鿡°Ô µµ¿òÀ» ÁÝ´Ï´Ù. ECCO2RÀº CO2 ¼öÁØÀ» ³·ÃãÀ¸·Î½á È£Èí ±â´ÉÀ» ¾ÈÁ¤È­½ÃÄÑ Æó ¼Õ»óÀ» À¯¹ßÇÒ ¼ö ÀÖ´Â °í¾Ð ÀΰøÈ£Èí±â¸¦ ÇÊ¿ä·Î ÇÏÁö ¾Ê´Â ÁßÁõ ȯÀÚ °ü¸®¿¡ ƯÈ÷ À¯¿ëÇϸç, ÆóÀÇ È޽İú ȸº¹À» µ½½À´Ï´Ù. ¶ÇÇÑ ÈÞ´ë°¡ °£ÆíÇÏ°í »ç¿ëÇϱ⠽¬¿î ¹öÀüÀÌ °³¹ßµÇ¾î ÁßȯÀÚ½Ç ¹Û¿¡¼­µµ »ç¿ëÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, ¸¸¼º È£Èí±â °ü¸®ÀÇ À¯¸ÁÇÑ ¼Ö·ç¼ÇÀÌ µÇ°í ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀüÀº ECCO2R ½ÃÀåÀ» ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

ÀÇ·á ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀ¸·Î ECCO2R Àåºñ´Â ´õ¿í È¿À²ÀûÀ̰í ÄÄÆÑÆ®ÇØÁ® ´Ù¾çÇÑ È¯ÀÚÀÇ ¿ä±¸¿¡ ÀûÀÀÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½Å¿¡´Â ÇÕº´Áõ°ú °¨¿°À» ÃÖ¼ÒÈ­ÇÏ´Â »ýüÀûÇÕ¼º Àç·áÀÇ ÅëÇÕ°ú °¢ ȯÀÚÀÇ Æ¯Á¤ »óÅ¿¡ ¸Â´Â Á¤È®ÇÑ CO2 Á¦°Å¸¦ º¸ÀåÇϴ ÷´Ü ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ »ç¿ëÀÌ Æ÷ÇԵ˴ϴÙ. ÀÇ·á ºÐ¾ßÀÇ Àúħ½ÀÀû Á¢±Ù ¹æ½Ä¿¡ ´ëÇÑ Ãß¼¼´Â º¸´Ù ħ½ÀÀûÀÌÁö ¾ÊÀº ECCO2R ÀåºñÀÇ ¼³°è·Î À̾îÁ® º¸´Ù ºü¸¥ ¼³Ä¡¿Í ±âÁ¸ È£Èí º¸Á¶ ½Ã½ºÅÛ°úÀÇ ÅëÇÕÀ» ¿ëÀÌÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ °¢ ¾÷üµéÀº º´¿ø°ú ÀçÅà ġ·á ȯ°æ ¸ðµÎ¿¡ À¯¿¬ÇÏ°Ô Àû¿ëÇÒ ¼ö ÀÖ´Â ÈÞ´ë¿ë ±â±â °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, ¸¸¼ºÁúȯ °ü¸®¿¡ »õ·Î¿î ±æÀ» ¿­¾î°¡°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î ECCO2R Àåºñ´Â È£Èí±â Áúȯ °ü¸®¿¡ ÀÖÀ¸¸ç, ¸Å¿ì Áß¿äÇÑ ¿ä¼Ò·Î ÀÚ¸®¸Å±èÇϰí ÀÖÀ¸¸ç, ÀÇ·á ºñ¿ëÀ» Àý°¨Çϰí ȯÀÚ ¿¹Èĸ¦ °³¼±Çϰí ÀÖ½À´Ï´Ù.

ECCO2R ÀåºñÀÇ »õ·Î¿î ÀÀ¿ë ¹× µ¿ÇâÀº?

ECCO2R Àåºñ ½ÃÀåÀº ±× ¿ëµµ°¡ ±âÁ¸ÀÇ º´¿ø ȯ°æÀ» ³Ñ¾î È®´ëµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ¸¸¼º È£Èí±â ÁúȯÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ECCO2R Àåºñ´Â ƯÈ÷ ¿Ü·¡ ȯÀÚ ¹× ÀçÅÃÄ¡·á ȯ°æ¿¡¼­ Àå±â °ü¸® ¼Ö·ç¼ÇÀ¸·Î °í·ÁµÇ°í ÀÖ½À´Ï´Ù. ÀÇ·áÁøµéÀº ±âÁ¸ÀÇ ¹æ¹ýÀ¸·Î´Â È¿°ú°¡ ¾ø°Å³ª ÇÕº´Áõ À§ÇèÀÌ ÀÖ´Â ÁßȯÀÚ Ä¡·á »óȲ¿¡¼­ ECCO2R ÀåºñÀÇ Ã¤ÅÃÀ» ´Ã¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ È¿°úÀûÀΠȣÈí º¸Á¶ ÀåºñÀÇ Çʿ伺ÀÌ ºÎ°¢µÇ¸é¼­ ECCO2RÀÇ È¿À²¼º°ú Á¢±Ù¼ºÀ» °³¼±Çϱâ À§ÇÑ ¿¬±¸°³¹ß ³ë·ÂÀÌ ´õ¿í Ȱ¹ßÇØÁö°í ÀÖ½À´Ï´Ù. ȯÀÚÀÇ À̵¿¼º°ú Æí¾ÈÇÔ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ Á¦Á¶¾÷üµéÀº ÀÀ±Þ½Ç°ú ¾ßÀüº´¿øÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ Ä¡·á ȯ°æ¿¡¼­ »ç¿ëÇÒ ¼ö ÀÖ´Â ´õ °¡º±°í ´Ù¿ëµµÇÑ Àåºñ¸¦ »ý»êÇϱâ À§ÇØ ±â¼ú Çõ½Å¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

ECCO2R ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

ECCO2R ½ÃÀåÀÇ ¼ºÀåÀº È¿°úÀûÀÎ CO2 °ü¸® ¼Ö·ç¼ÇÀ» ÇÊ¿ä·Î ÇÏ´Â COPD ¹× ARDS¿Í °°Àº È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í °°Àº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖÀ¸¸ç, COVID-19 ÆÒµ¥¹ÍÀÇ ¿µÇâÀº °í±Þ È£Èí Áö¿ø ±â¼úÀÇ Çʿ伺À» °­Á¶ÇÏ¸ç ¼ö¿ä¸¦ ´õ¿í ÀÚ±ØÇϰí ÀÖ½À´Ï´Ù. ¼ö¿ä¸¦ ´õ¿í ÀÚ±ØÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ »ýü ÀûÇÕ¼º ¹× ÃÖ¼Ò Ä§½À¼º ECCO2R ÀåºñÀÇ °³¹ß°ú °°Àº ±â¼ú Çõ½ÅÀº ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡¼­ ÀÌ·¯ÇÑ ½Ã½ºÅÛÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ȯÀÚÀÇ ¼±È£µµ¿Í ÀÇ·áºñ Àý°¨ÀÇ Çʿ伺¿¡ ÈûÀÔ¾î ÈÞ´ë¿ë ¹× ȨÄɾî¿ë È£Èí±â ¼Ö·ç¼ÇÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ÇコÄɾî ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ¿Í È£Èí±â Àåºñ¿¡ ´ëÇÑ ±â¼ú Çõ½Å Áõ°¡´Â ECCO2R ºÐ¾ß¿¡ Å« ¼ºÀå ±âȸ¸¦ °¡Á®´Ù ÁÙ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÎ¹®

Á¦Ç°(ü¿Ü CO2 ±â°è, ÀÏȸ¿ë, ±âŸ Á¦Ç°); & Á¢±Ù(Á¤¸Æ, µ¿Á¤¸Æ); & ¿ëµµ(ÆóÀÌ½Ä ±³·®, ±Þ¼ºÈ£Èí°ï¶õÁõÈıº(ARDS), ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), ±âŸ ¿ëµµ); & ÃÖÁ¾ ¿ëµµ(º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ, Ŭ¸®´Ð, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 44»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Extracorporeal CO2 Removal Devices Market to Reach US$151.9 Million by 2030

The global market for Extracorporeal CO2 Removal Devices estimated at US$107.3 Million in the year 2024, is expected to reach US$151.9 Million by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Extracorporeal CO2 Machines, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$89.9 Million by the end of the analysis period. Growth in the Disposables segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$29.4 Million While China is Forecast to Grow at 5.5% CAGR

The Extracorporeal CO2 Removal Devices market in the U.S. is estimated at US$29.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$23.6 Million by the year 2030 trailing a CAGR of 5.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.1% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Extracorporeal CO2 Removal Devices Market - Key Trends & Drivers Summarized

Why Are Extracorporeal CO2 Removal Devices Critical for Respiratory Care?

Extracorporeal CO2 removal (ECCO2R) devices have become vital in the management of severe respiratory conditions, offering a less invasive alternative to traditional ventilation. ECCO2R devices function by removing carbon dioxide (CO2) from the patient’s blood externally, providing relief for patients with chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and other lung disorders where CO2 accumulation is a critical concern. These devices are particularly beneficial in managing severe cases without the need for high-pressure mechanical ventilation, which can cause further lung injury. By reducing CO2 levels, ECCO2R devices help stabilize respiratory functions, allowing the lungs to rest and recover. The development of portable and user-friendly versions of these devices is also expanding their use beyond intensive care units, making them a promising solution for chronic respiratory management.

How Are Technological Advancements Shaping the ECCO2R Market?

With continuous advancements in medical technology, ECCO2R devices are becoming more efficient, compact, and adaptable to various patient needs. Innovations include integrating biocompatible materials that minimize complications and infections, and the use of advanced monitoring systems that ensure precise CO2 removal tailored to each patient’s specific condition. The trend toward minimally invasive approaches in healthcare has also led to the design of ECCO2R devices that are less intrusive, enabling quicker setup and easier integration into existing respiratory support systems. Additionally, companies are focusing on developing portable devices that offer greater flexibility for both in-hospital and home care settings, opening new avenues for chronic condition management. These advancements are making ECCO2R devices a pivotal component in the management of respiratory diseases, enhancing patient outcomes while reducing healthcare costs.

What Are the Emerging Applications and Trends in ECCO2R Devices?

The market for ECCO2R devices is expanding as their applications extend beyond traditional hospital settings. With increasing incidences of chronic respiratory diseases globally, these devices are now being explored for long-term management solutions, especially in outpatient and home-care environments. Medical practitioners are increasingly adopting ECCO2R devices for critical care scenarios where traditional methods might be ineffective or pose risks of complications. Furthermore, the COVID-19 pandemic has highlighted the need for effective respiratory support devices, boosting the research and development efforts towards improving ECCO2R efficiency and accessibility. The growing emphasis on patient mobility and comfort is also pushing manufacturers to innovate, producing lighter and more versatile devices that can be used in diverse care settings, including emergency response units and field hospitals.

What Factors Are Fueling the Growth of the ECCO2R Market?

The growth in the ECCO2R market is driven by several factors, including the increasing prevalence of respiratory diseases such as COPD and ARDS, which demand effective CO2 management solutions. The impact of the COVID-19 pandemic has also underscored the necessity for advanced respiratory support technologies, further stimulating demand. Additionally, technological innovations, such as the development of biocompatible and minimally invasive ECCO2R devices, are enhancing the adoption of these systems in various healthcare settings. The push towards portable and home-care respiratory solutions, fueled by patient preference and the need for healthcare cost reduction, is further accelerating the market’s growth. Rising investments in healthcare infrastructure and respiratory device innovation, particularly in emerging markets, are expected to create significant growth opportunities in the ECCO2R sector.

SCOPE OF STUDY:

The report analyzes the Extracorporeal CO2 Removal Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Extracorporeal CO2 Machines, Disposables, Other Products); Access (Venovenous, Arteriovenous); Application (Bridge To Lung Transplant, Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD), Other Applications); End-Use (Hospitals, Ambulatory Surgery Centers, Clinics, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â